Gilead Sciences - GILD Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings or view top-rated stocks.

17 Wall Street analysts have issued twelve-month price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $69.00 to $111.00. On average, they anticipate the company's share price to reach $87.40 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price.
View analysts price targets for GILD or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $85.85 at the beginning of the year. Since then, GILD shares have decreased by 2.9% and is now trading at $83.35.
View the best growth stocks for 2023 here.

Gilead Sciences saw a decrease in short interest in January. As of January 15th, there was short interest totaling 14,930,000 shares, a decrease of 8.0% from the December 31st total of 16,220,000 shares. Based on an average daily trading volume, of 7,960,000 shares, the short-interest ratio is currently 1.9 days.
View Gilead Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our GILD earnings forecast.

Gilead Sciences will be holding an earnings conference call on Thursday, February 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Thursday, October, 28th. The biopharmaceutical company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.93. The biopharmaceutical company had revenue of $7.42 billion for the quarter, compared to the consensus estimate of $6.31 billion. Gilead Sciences had a trailing twelve-month return on equity of 38.51% and a net margin of 12.29%. Gilead Sciences's revenue was up 12.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.11 earnings per share.
Read the conference call transcript.

Gilead Sciences declared a quarterly dividend on Thursday, October 27th. Investors of record on Thursday, December 15th will be paid a dividend of $0.73 per share on Thursday, December 29th. This represents a $2.92 annualized dividend and a yield of 3.50%. The ex-dividend date is Wednesday, December 14th.
Read our dividend analysis for GILD.

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 3.49%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 110.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 43.13% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

Gilead Sciences updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of $6.95-$7.15 for the period, compared to the consensus estimate of $6.54. The company issued revenue guidance of $25.90 billion-$26.20 billion, compared to the consensus revenue estimate of $25.25 billion.

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Parnassus Investments LLC (0.96%), Sumitomo Mitsui Trust Holdings Inc. (0.34%), Railway Pension Investments Ltd (0.19%), New York State Common Retirement Fund (0.19%), Allspring Global Investments Holdings LLC (0.12%) and New York State Teachers Retirement System (0.12%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $83.35.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $104.54 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $2.65 on an earnings per share basis.

The company employs 14,400 workers across the globe.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.